Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.
Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, Georgopali A, Goldenberg SD, Karas A, Kazeem G, Longshaw C, Palacios-Fabrega JA, Cornely OA, Vehreschild MJGT; EXTEND Clinical Study Group. Guery B, et al. Among authors: georgopali a. Lancet Infect Dis. 2018 Mar;18(3):296-307. doi: 10.1016/S1473-3099(17)30751-X. Epub 2017 Dec 19. Lancet Infect Dis. 2018. PMID: 29273269 Clinical Trial.
Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).
Vehreschild MJGT, Taori S, Goldenberg SD, Thalhammer F, Bouza E, van Oene J, Wetherill G, Georgopali A. Vehreschild MJGT, et al. Among authors: georgopali a. Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2097-2106. doi: 10.1007/s10096-018-3344-1. Epub 2018 Aug 11. Eur J Clin Microbiol Infect Dis. 2018. PMID: 30099637 Free PMC article.
Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study.
Wilcox MH, Cornely OA, Guery B, Longshaw C, Georgopali A, Karas A, Kazeem G, Palacios-Fabrega JA, Vehreschild MJGT. Wilcox MH, et al. Among authors: georgopali a. Open Forum Infect Dis. 2019 Nov 6;6(11):ofz436. doi: 10.1093/ofid/ofz436. eCollection 2019 Nov. Open Forum Infect Dis. 2019. PMID: 31723569 Free PMC article.
Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial.
Guery B, Georgopali A, Karas A, Kazeem G, Michon I, Wilcox MH, Cornely OA. Guery B, et al. Among authors: georgopali a. J Antimicrob Chemother. 2020 Apr 1;75(4):1014-1018. doi: 10.1093/jac/dkz549. J Antimicrob Chemother. 2020. PMID: 31960058 Free article. Clinical Trial.
Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: an open-label Phase IIIb/IV study (PROFILE).
Högenauer C, Mahida Y, Stallmach A, Marteau P, Rydzewska G, Ivashkin V, Gargalianos-Kakolyris P, Michon I, Adomakoh N, Georgopali A, Tretter R, Karas A, Reinisch W. Högenauer C, et al. Among authors: georgopali a. J Antimicrob Chemother. 2018 Dec 1;73(12):3430-3441. doi: 10.1093/jac/dky368. J Antimicrob Chemother. 2018. PMID: 30260412 Clinical Trial.
Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).
Vehreschild MJGT, Taori S, Goldenberg SD, Thalhammer F, Bouza E, van Oene J, Wetherill G, Georgopali A. Vehreschild MJGT, et al. Among authors: georgopali a. Eur J Clin Microbiol Infect Dis. 2019 Jan;38(1):199. doi: 10.1007/s10096-018-3410-8. Eur J Clin Microbiol Infect Dis. 2019. PMID: 30406879 Free PMC article.
Point-prevalence survey of healthcare facility-onset healthcare-associated Clostridium difficile infection in Greek hospitals outside the intensive care unit: The C. DEFINE study.
Skoutelis A, Pefanis A, Tsiodras S, Sipsas NV, Lelekis M, Lazanas MC, Gargalianos P, Dalekos GN, Roilides E, Samonis G, Maltezos E, Hatzigeorgiou D, Lada M, Metallidis S, Stoupis A, Chrysos G, Karnesis L, Symbardi S, Loupa CV, Giamarellou H, Kioumis I, Sambatakou H, Tsianos E, Kotsopoulou M, Georgopali A, Liakou K, Perlorentzou S, Levidiotou S, Giotsa-Toutouza M, Tsorlini-Christoforidou H, Karaiskos I, Kouppari G, Trikka-Graphakos E, Ntrivala MA, Themeli-Digalaki K, Pangalis A, Kachrimanidou M, Martsoukou M, Karapsias S, Panopoulou M, Maraki S, Orfanou A, Petinaki E, Orfanidou M, Baka V, Stylianakis A, Spiliopoulou I, Smilakou S, Zerva L, Vogiatzakis E, Belesiotou E, Gogos CA. Skoutelis A, et al. Among authors: georgopali a. PLoS One. 2017 Aug 16;12(8):e0182799. doi: 10.1371/journal.pone.0182799. eCollection 2017. PLoS One. 2017. PMID: 28813492 Free PMC article.